Comprehensive analysis on the implications of IAH1 in cancer development and progression.

Chuanchuan Sun, Xianghong Wang, Yeye Yu, Heng Shi, Fanna Liu, Shiping Zhu, Shengyun Sun

Abstract readReview

In one paragraph

Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chuanchuan SunDepartment of Nephrology, Peking University International Hospital, Beijing, China.

Xianghong WangDepartment of Endocrinology, Wuhan Fourth Hospital, Wuhan, China.

Yeye YuDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Heng ShiDepartment of Gastroenterology, The Central Hospital of Shaoyang, Shaoyang, China.

Fanna LiuDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Shiping ZhuDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Shengyun SunDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to elucidate the role of the IAH1 gene across multiple cancer types. Methods: Using multi-omics data from public databases including TCGA, GTEx, TIMER, and cBioPortal, we analyzed the expression patterns of IAH1 and their correlations with prognostic outcomes, immune cell infiltration, immune checkpoint markers, tumor mutational burden (TMB), microsatellite instability (MSI), response to immunotherapy, and drug sensitivity through bioinformatic tools and R software. Results: IAH1 expression was significantly upregulated in most cancers and associated with adverse prognosis. Elevated IAH1 levels correlated strongly with immune-related gene expression, immune checkpoint levels, TMB, MSI, and immune infiltration. Moreover, IAH1 expression was linked to sensitivity to anticancer drugs and survival outcomes following immune checkpoint inhibitor (ICI) treatment. Conclusions: IAH1 may serve as a promising immunoregulatory target and potential biomarker for diagnosis and prognosis in specific cancers.

Indexed as

Drug sensitivityIAH1Immune infiltrationImmunotherapyPan-cancerPrognosis

Identifiers

PMID41311370

DOI10.1016/j.bbrep.2025.102287

PMCPMC12650796

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.